Atara Biotherapeutics: Q4 Earnings Insights

Atara Biotherapeutics (NASDAQ:ATRA) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:30 AM. Here’s what…

Atara Biotherapeutics (NASDAQ:ATRA) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:30 AM.

Here’s what investors need to know about the announcement.

Earnings

Atara Biotherapeutics missed estimated earnings by -17.0%, reporting an EPS of $-0.56 versus an estimate of $-0.48.

Revenue was up $4.03 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.0 which was followed by a 6.0% drop in the share price the next day.

Here’s a look at Atara Biotherapeutics’s past performance:

Quarter Q3 2023 Q2 2023 Q1 2023
EPS Estimate -0.66 -0.67 -0.39
EPS Actual -0.66 -0.68 -0.72
Revenue Estimate 4.76M 3.77M 30.68M
Revenue Actual 2.14M 957K 1.23M

To track all earnings releases for Atara Biotherapeutics visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Imax Reports Better-Than-Expected Q1 Results

Imax reported quarterly earnings of 15 cents per share which beat the analyst consensus estimate of 10 cents by 50%. Quarterly sales of $79.12 million beat the analyst consensus estimate of $78.18 million by 1.21%. The company reported 15 Imax system installations in the first quarter, up 67% year-over-year and 17 signings for new and upgraded IMAX systems worldwide year-to-date.

IMAX